Polsinelli Health Care Litigation attorneys combine their in-depth knowledge of the evolving health care industry with clients’ business needs to devise practical litigation strategies. We advise clients in managing risk and resolving complex disputes. When litigation is necessary, we collaborate with clients to effectively and efficiently protect their interests. Our attorneys are experienced in litigating government investigations and health care disputes in different forums, including lawsuits, arbitrations, administrative hearings, audits and investigations.

Our team is well known and respected by judges, regulators, arbitrators, health care industry leaders and the legal community. Members include former Department of Justice attorneys, including Assistant United States Attorneys, former experienced state Medicaid fraud unit attorneys, a former realtor attorney and former in-house counsel to private and publicly traded health care companies.

Honors achieved by our litigators include:

  • Fellows of the American College of Trial Lawyers
  • Chambers USA: America’s Leading Lawyers for Healthcare
  • Benchmark Litigation: The Definitive Guide to America’s Leading Litigation Firms and Attorneys
  • Best Lawyers in America®

We also routinely draw upon the knowledge and experience of our firm’s Health Care Department, which is nationally recognized and one of the largest in the country, to assist our clients. This group consists of former pharmacists and nurses, a former attorney with the Department of Health and Human Services, a former director of a state Medicaid program, a former FDA attorney and Medicaid, Medicare and HIPAA specialists.

Our clients include several of the country’s top hospital systems, research facilities, publicly traded companies, specialty pharmacies, laboratories, medical and osteopathic educational institutions and associations, infusion providers, home health and hospice providers, long term care facilities, dialysis providers, ambulatory surgery centers, PMBs and HME/DME suppliers.

Our government investigations and health care litigation services include:

  • Government Investigations
  • False Claims Act Defense
  • Managed Care & Payor Disputes
  • Reimbursement Audits & Disputes
  • Surprise Billing Disputes
  • Medical Staff & Governance, Operations & Disputes
  • Commercial Disputes
  • HIPAA & Privacy
  • RAC Audits & Appeals
  • Administrative Hearings
  • Medical & Osteopathic Accreditation & Programming
  • Biometric Privacy Disputes
  • Guardianships
  • Certificate of Need
  • Antitrust
  • Unfair Competition, Misappropriation of Trade Secrets & Restrictive Covenants
  • Class Actions
  • Exempt Status Litigation
  • Pharmacy Board Hearings
  • Provider Malpractice/Risk Management
Publications
Polsinelli Life Sciences Spotlight - Volume 3 - Turning Insight into Action: A Life Sciences Playbook for 2026
We are pleased to share Volume 3 of our Life Sciences Spotlight: Turning Insight into Action: A Life Sciences Playbook for 2026. We look back at a year defined by resilience and ahead to one shaped by opportunity. From M&A readiness and FDA reform to AI-driven innovation and enforcement risk, this edition delivers practical guidance for navigating what’s next. M&A-Ready from Day One Reshaping the FDA: 2025’s Key Trends and the 2026 Outlook Fraud & Abuse Enforcement in the Life Sciences: The Year In Review From Scattered Logs to Connected Insight: How Eschbach is Transforming Frontline Documentation in Life Sciences When Biology Meets Computing: The Patent Challenges of Bioinformatics University Tech Transfer in Transition: Highlights from Polsinelli’s Life Sciences Tech Transfer Office Roundtable Practical Strategies for Drug Labeling Amendments 
Read More
CMS Finalizes Sweeping Reforms to Skin Substitute Payments Amid Rising Costs and Enforcement Activity
Key Takeaways: Major Financial and Operational Impact: On Nov. 5, 2025, CMS finalized a rule that fundamentally changes Medicare payment methodology for a broad range of skin substitute products used for wound care. Beginning in January 2026, most skin substitute products will shift from average sales price (ASP)-based payments to a flat, standardized rate. For 2026, that rate is $127.28/cm2 — likely reflecting a major payment cut for most products. Heightened Enforcement: With significant increases in spending over the past several years, wound care and skin substitutes have been in the spotlight for regulators. Despite the change in payment methodology, enforcement activity is likely to continue, with a focus on medical necessity of treatments and pricing.  Starting Jan. 1, 2026, Medicare will overhaul
Read More